CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation

Cell Proliferation

Volumn 44, Issue 4, 2011, Pages 311-319

  El Haibi, C P ^a   Singh, R ^b   Sharma, P K ^c   Singh, S ^b   Lillard, J W ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

^c CENTRAL UNIVERSITY OF JHARKHAND   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE; CXCL13 CHEMOKINE; DEDICATOR OF CYTOKINESIS 2; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAST ACTIVATED CELL BASED; IMMUNOBLOTTING; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL13; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; ONCOGENE PROTEIN V-AKT; PROSTATIC NEOPLASMS; RECEPTORS, CXCR5; SIGNAL TRANSDUCTION;

EID: 79959765107     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2011.00757.x     Document Type: Article

References (44)

1. Walczak JR, Carducci MA (2007) Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin. Proc. 82, 243-249.
2. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M (2008) Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract. Res. Clin. Endocrinol. Metab. 22, 341-355.
3. Klocker H, Culig Z, Kaspar F, Hobisch A, Eberle J, Reissigl A et al. (1994) Androgen signal transduction and prostatic carcinoma. World J. Urol. 12, 99-103.
4. Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int. 95, 1327-1335.
5. Kakinuma T, Hwang ST (2006) Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol. 79, 639-651.
6. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I (2007) Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 98, 1652-1658.
7. Rodriguez-Frade JM, Martinez AC, Mellado M (2005) Chemokine signaling defines novel targets for therapeutic intervention. Mini Rev. Med. Chem. 5, 781-789.
8. Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267, 226-244.
9. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LWK et al. (2009) Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int. J. Cancer 125, 2288-2295.
10. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LWK et al. (2009) Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 283, 29-35.
11. Lisignoli G, Toneguzzi S, Piacentini A, Cattini L, Lenti A, Tschon M et al. (2003) Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J. Cell. Physiol. 194, 71-79.
12. Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med. 9, 59-71.
13. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A et al. (2007) R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J. Cell. Physiol. 211, 533-543.
14. Kue PF, Daaka Y (2000) Essential role for G proteins in prostate cancer cell growth and signaling. J. Urol. 164, 2162-2167.
15. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ et al. (2007) Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11, 555-569.
16. Durand CA, Westendorf J, Tse KW, Gold MR (2006) The Rap GTPases mediate CXCL13- and sphingosine1-phosphate-induced chemotaxis, adhesion, and Pyk2 tyrosine phosphorylation in B lymphocytes. Eur. J. Immunol. 36, 2235-2249.
17. Weston CR, Davis RJ (2002) The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12, 14-21.
18. Sanui T, Inayoshi A, Noda M, Iwata E, Stein JV, Sasazuki T et al. (2003) DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1. Blood 102, 2948-2950.
19. Chung CY, Lee S, Briscoe C, Ellsworth C, Firtel RA (2000) Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells. Proc. Natl. Acad. Sci. USA 97, 5225-5230.
20. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe M et al. (2001) Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412, 826-831.
21. Kunisaki Y, Tanaka Y, Sanui T, Inayoshi A, Noda M, Nakayama T et al. (2006) DOCK2 is required in T cell precursors for development of Valpha14 NK T cells. J. Immunol. 176, 4640-4645.
22. Nombela-Arrieta C, Mempel TR, Soriano SF, Mazo I, Wymann MP, Hirsch E et al. (2007) A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. J. Exp. Med. 204, 497-510.
23. Cotton M, Claing A (2009) G protein-coupled receptors stimulation and the control of cell migration. Cell. Signal. 21, 1045-1053.
24. Zlotnik A (2006) Chemokines and cancer. Int. J. Cancer 119, 2026-2029.
25. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
26. Kandel ES, Hay N (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253, 210-229.
27. Fang J, Ding M, Yang L, Liu LZ, Jiang BH (2007) PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell. Signal. 19, 2487-2497.
28. Ghosh PM, Malik S, Bedolla R, Kreisberg JI (2003) Akt in prostate cancer: possible role in androgen-independence. Curr. Drug Metab. 4, 487-496.
29. Blanco-Aparicio C, Renner O, Leal JF, Carnero A (2007) PTEN, more than the AKT pathway. Carcinogenesis 28, 1379-1386.
30. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
31. Maitland NJ, Macintosh CA, Hall J, Sharrard M, Quinn G, Lang S (2001) In vitro models to study cellular differentiation and function in human prostate cancers. Radiat. Res. 155, 133-142.
32. Mitchell S, Abel P, Ware M, Stamp G, Lalani E (2000) Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int. 85, 932-944.
33. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W et al. (2003) AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol. Cell. Biol. 23, 104-118.
34. Ridley AJ (2001) Rho family proteins: coordinating cell responses. Trends Cell Biol. 11, 471-477.
35. Nishihara H, Maeda M, Oda A, Tsuda M, Sawa H, Nagashima K et al. (2002) DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood 100, 3968-3974.
36. Shulman Z, Pasvolsky R, Woolf E, Grabovsky V, Feigelson SW, Erez N et al. (2006) DOCK2 regulates chemokine-triggered lateral lymphocyte motility but not transendothelial migration. Blood 108, 2150-2158.
37. Delcourt N, Bockaert J, Marin P (2007) GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol. Sci. 28, 602-607.
38. Piiper A, Zeuzem S (2004) Receptor tyrosine kinases are signaling intermediates of G protein-coupled receptors. Curr. Pharm. Des. 10, 3539-3545.
39. Smith A, Ramos-Morales F, Ashworth A, Collins M (1997) A role for JNK/SAPK in proliferation, but not apoptosis, of IL-3-dependent cells. Curr. Biol. 7, 893-896.
40. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS et al. (2003) C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin. Cancer Res. 9, 391-401.
41. Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M et al. (2005) Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J. Pharmacol. Exp. Ther. 313, 325-332.
42. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL (2004) Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23, 596-604.
43. Sundberg LJ, Galante LM, Bill HM, Mack CP, Taylor JM (2003) An endogenous inhibitor of focal adhesion kinase blocks Rac1/JNK but not Ras/ERK-dependent signaling in vascular smooth muscle cells. J. Biol. Chem. 278, 29783-29791.
44. Heasley LE, Han SY (2006) JNK regulation of oncogenesis. Mol. Cells 21, 167-173.